Skip to Content
Merck
CN
  • Improved therapeutic efficacy of mammalian expressed-recombinant interferon gamma against ovarian cancer cells.

Improved therapeutic efficacy of mammalian expressed-recombinant interferon gamma against ovarian cancer cells.

Experimental cell research (2017-08-15)
Ali Razaghi, Carina Villacrés, Vincent Jung, Narges Mashkour, Michael Butler, Leigh Owens, Kirsten Heimann
ABSTRACT

Human interferon gamma (hIFNγ) affects tumour cells and modulates immune responses, showing promise as an anti-cancer biotherapeutic. This study investigated the effect of glycosylation and expression system of recombinant hIFNγ in ovarian carcinoma cell lines, PEO1 and SKOV3. The efficacy of E. coli- and mammalian-expressed hIFNγ (hIFNγ-CHO and HEK293, glycosylated/de-glycosylated) on cytostasis, cell death (MTT, and Guava-ViaCount

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
RPMI-1640 Medium, With L-glutamine and sodium bicarbonate, liquid, sterile-filtered, suitable for cell culture
Sigma-Aldrich
Glycoprofile II, Enzymatic In-Solution N-Deglycosylation Kit, sufficient for 20 samples